Table 3 Some of ongoing clinical studies of iron-based nanomaterials for tumor imaging and therapy
From: Recent progress of iron-based nanomaterials in gene delivery and tumor gene therapy
NCT Number | Drugs | Indications | Sponsor | Phase |
|---|---|---|---|---|
NCT02033447 | Magnablate I | Thermoablation-Retention and Maintenance in the Prostate | University College London Hospitals | Early Phase 1 |
NCT02751606 | Ferumoxtran-10 | Rectal and Breast cancer | Radboud University Medical Center | Phase 3 |
NCT00188695 | Ferumoxtran-10 | Prostate (cT1-cT3) or bladder cancer | University Health Network, Toronto | Phase 1 and 2 |
NCT04682847 | Ferumoxytol injection | Primary & Metastatic Hepatic Cancers | Allegheny Singer Research Institute | Not Provided |
NCT05092750 | Magnetic Particle-ICG | Lymph Node Mapping in Colorectal Cancer | M.D. Anderson Cancer Center | Phase 1 and 2 |
NCT06271421 | NanoTherm | Adjuvant Therapy of Glioblastoma Multiforme | Poznan University of Medical Sciences | Not Provided |
NCT04484909 | NBTXR3 | Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer | M.D. Anderson Cancer Center | Phase 1 |
NCT02442531 | CriPec® docetaxel | Docetaxel Given to Patients With Solid Tumours | Cristal Therapeutics | Phase 1 |